Milwaukee City Wire

Senator Ron Johnson, a Republican representing Wisconsin, has recently made several public statements on his social media account addressing federal spending, drug policy reform, and international health regulations.

On July 18, 2025, Johnson commented on federal fiscal management: "DOGE has identified approximately $190 billion in waste, fraud, and abuse. Meanwhile, we’re on track to spend $7 trillion this year, with a projected deficit of about $1.9 trillion for the fifth year in a row.

If the administration thinks we should cut money from the federal https://t.co/PjzbwO0aK7" The senator referenced findings by the Department of Government Oversight and Efficiency (DOGE) regarding inefficiencies in government expenditures and highlighted concerns over ongoing large-scale deficits.

Later that day, Johnson acknowledged two Wisconsin residents for their role in recent legislative developments: "Congratulations to Wisconsinites Lauri Badura and Tim Westlake on the signing of the HALT Fentanyl Act yesterday.

Thank you to Lauri and Tim for your tireless efforts to move fentanyl to a Schedule I classification under the Controlled Substances Act. This will save lives. https://t.co/wkP5Ctd0uD" His remarks followed congressional action reclassifying fentanyl as a Schedule I substance—an effort intended to strengthen legal controls around synthetic opioids amid rising overdose deaths nationwide.

On July 19, 2025, Johnson addressed U.S. positions on global health governance: "I applaud @SecKennedy and @SecRubio for formally rejecting the dangerous IHR amendments. The Biden Administration tried to surrender our sovereignty to the WHO.

America should not allow unelected global bureaucrats to dictate our health policy. This is a huge win for medical https://t.co/0Migk8WW0n" He expressed support for officials who opposed proposed amendments to International Health Regulations (IHR), emphasizing national autonomy over public health decisions.

The senator's comments come at a time when debates continue over federal budget priorities and regulatory responses both domestically—such as measures against opioid abuse—and internationally regarding U.S. participation in multilateral health agreements.